Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

44.17
+0.49001.12%
Post-market: 44.170.00000.00%19:45 EDT
Volume:3.14M
Turnover:138.52M
Market Cap:11.22B
PE:15.89
High:44.32
Open:43.51
Low:43.50
Close:43.68
52wk High:49.62
52wk Low:33.76
Shares:254.01M
Float Shares:206.00M
Volume Ratio:1.30
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.78
ROE:35.53%
ROA:19.27%
PB:5.19
PE(LYR):15.89

Loading ...

Earning Preview: Exelixis Q1 revenue is expected to increase by 21.51%, and institutional views are cautious with Hold calls dominant

Earnings Agent
·
Apr 28

Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL

TIPRANKS
·
Apr 24

Does Exelixis (EXEL) Gain Quiet Competitive Leverage From a Rival’s Kidney Cancer Setback?

Simply Wall St.
·
Apr 23

The Tactical Trio Blueprint For Solid Balance Sheet And Fundamentals

Simply Wall St.
·
Apr 22

Exelixis schedules quarterly results release and conference call

Reuters
·
Apr 22

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Apr 20

A Look At Exelixis (EXEL) Valuation As CABOMETYX Growth And Trial Outlook Shape Expectations

Simply Wall St.
·
Apr 17

Exelixis publishes 2025 annual report

Reuters
·
Apr 16

Exelixis announces annual shareholder meeting

Reuters
·
Apr 16

Wells Fargo Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Apr 14

Exelixis (EXEL) Gets a Hold from RBC Capital

TIPRANKS
·
Apr 09

Wells Fargo Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Apr 02

Genmab names Margarida Duarte general manager for Europe and emerging markets

Reuters
·
Apr 01

Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)

TIPRANKS
·
Mar 25

Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts

Simply Wall St.
·
Mar 13

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)

TIPRANKS
·
Mar 09

A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline

Simply Wall St.
·
Mar 05

Exelixis Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Mar 03

Exelixis price target lowered to $43 from $46 at RBC Capital

TIPRANKS
·
Mar 02

RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating

MT Newswires Live
·
Mar 02